Alnylam has been a trailblazer in the development of RNAi therapeutics

Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam has been a trailblazer in the development of RNAi therapeutics. Over more than two decades, the company’s relentless pursuit of scientific breakthroughs has laid the foundation for this new class of medicines, which harnesses the body’s natural processes to target and silence harmful genes. Alnylam’s pioneering work reached a significant milestone in 2018 with the approval of its first commercial medicine, marking the world’s first RNAi therapeutic to gain regulatory approval. This achievement was a monumental step not only for Alnylam but also for the entire field of RNAi therapeutics, demonstrating the potential of this technology to transform the treatment of diseases.